Eli Lilly Bolsters Drug Portfolio with Strategic Licensing Agreement
Published on 02/19/2026 at 12:03 | Redaktion boerse-global.de
Pharmaceutical giant Eli Lilly & Co. has secured exclusive rights to a promising anti-inflammatory drug, marking another strategic move in its ongoing campaign to expand its development pipeline. The company has entered into a licensing agreement with Australia’s CSL Limited, paying an upfront sum of $100 million for the asset known as clazakizumab.
Under the terms of the exclusive license, Eli Lilly gains worldwide rights to develop and commercialize clazakizumab for all indications excluding end-stage kidney disease (ESKD). CSL retains exclusive rights to advance the drug specifically for the prevention of cardiovascular events in ESKD patients, an area where a Phase 3 trial (POSIBIL 6 ESKD) is already underway.
The Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
